HOME › Research Insight › Development of Stem Cell Therapies of the Treatment of Various Diseases
Development of Stem Cell Therapies of the Treatment of Various Diseases
The stem cell therapy market includes large number of players that are involved in the development of stem cell therapies of the treatment of various diseases. Most of the stem cell therapies are under the different phases of clinical trials. The key players involved in the development of stem cell therapy market are Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.).
As of August 2013, Mesoblast Ltd. accounted for the largest number of stem cell-based clinical trials registered under ClinicalTrials.gov . The company's proprietary technologies include its mesenchymal precursor cell technology platform, its culture-expanded mesenchymal stem cells, dental pulp stem cells, and expanded hematopoietic stem cells. The company’s strong technological platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat major conditions with unmet medical needs. This enables it to maintain its leading position in the stem cell therapy market. Furthermore, the company focuses on acquisitions as its key business strategy, to ensure its growth in the global stem cell therapy market. Aligned with this strategy, in October 2013, Mesoblast Ltd. acquired Osiris Therapeutics (U.S.), a manufacturer of the world's first approved stem cell therapeutic product called prochymal stem cell therapy that is used in the treatment of graft-versus-host disease (GVHD).
Aastrom Biosciences, Inc. (U.S.) is the second significant player in the stem cell therapy market. It is a clinical-stage biotechnology company, which focuses on the development of regenerative medicines for use in the treatment of severe chronic ischemic cardiovascular diseases. The presence of proprietary highly automated and scalable manufacturing system for the development of patient-specific multicellular therapies serves as an important factor for its future growth. Its manufacturing technology platform, the Aastrom Replicell System (ARS), allows the expansion of a variety of cell types, which can be delivered directly to damage tissues using conventional syringes and cell injection catheter systems. In order to commercialize its stem cell therapy product in the market, the company has been concentrating on partnerships and agreements as its key business strategy.
StemCells, Inc. (U.S.) is also one of the significant players involved in the development of stem cell therapy products. It is engaged in the research, development, and commercialization of stem cell therapeutics for academia and industry. The company focuses on development and commercialization of stem cells and progenitor cells based novel therapies as well as related tools and technologies. This strategy enables StemCells, Inc. to maintain its position among the key players in the stem cell therapy market.
Approval of clinical trials and products, partnerships, agreements, collaborations, and joint ventures are the key growth strategies adopted by leading industry participants. Market players adopted these strategies to access new technologies, commercialize their products in short term, gain regulatory approvals, and/or increase their market visibility.
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252